FDA Approves Expanded Indication for Praluent to Lower LDL-C in Pediatric Patients with HeFH
Regeneron’s PCSK9 inhibitor approved to reduce low-density lipoprotein cholesterol in patients 8 years of age and older with heterozygous familial hypercholesterolemia.
